Coeptis Therapeutics Holdings Inc (COEP) is not a strong buy at this time for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks clear positive catalysts, has weak financial performance, and no significant trading signals or sentiment to support immediate investment. A hold position is recommended until better entry points or stronger growth indicators emerge.

Technical Analysis

The MACD is positive and expanding, which is a bullish signal. However, the RSI is neutral at 58.619, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The price is currently below the pivot level of 11.862, suggesting weak momentum. Key resistance levels are R1: 12.511 and R2: 12.913, while support levels are S1: 11.213 and S2: 10.811.

Positive Catalysts

The MACD histogram is positive and expanding, which could indicate potential upward momentum. Hedge funds and insiders are neutral, with no negative trading trends.

Neutral/Negative Catalysts

The stock price has declined both in regular market (-0.96%) and post-market (-2.03%). Moving averages are bearish, and there is no recent news or significant trading activity to support the stock. Financial performance is weak, with negative net income and declining EPS.

Financial Performance

In Q3 2025, revenue remained flat YoY at 237,441. Net income improved YoY but remains negative at -2,739,403. EPS dropped by 33.33% YoY to -0.58, and gross margin remains negative at -24.31%. Overall, the company's financials show no significant growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast COEP stock price to rise

Buy

Hold

Sell

Current: 11.440

Low

Averages

High